Today, Public Employees Retirement Association of Colorado Sold shares of DexCom Inc. (DXCM)

Today, Public Employees Retirement Association of Colorado Sold shares of DexCom Inc. (DXCM)

Public Employees Retirement Association of Colorado lowered its stake in shares of DexCom Inc. (NASDAQ:DXCM) by 2.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,993 shares of the medical device company’s stock after selling 473 shares during the period. Public Employees Retirement Association of Colorado’s holdings in DexCom were worth $1,665,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of DexCom by 59.3% in the second quarter. FMR LLC now owns 8,161,390 shares of the medical device company’s stock worth $647,443,000 after buying an additional 3,036,821 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of DexCom by 4.4% in the second quarter. Vanguard Group Inc. now owns 5,668,065 shares of the medical device company’s stock worth $449,648,000 after buying an additional 238,974 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of DexCom by 22.0% in the second quarter. Artisan Partners Limited Partnership now owns 5,591,101 shares of the medical device company’s stock worth $443,542,000 after buying an additional 1,008,260 shares during the last quarter. Waddell & Reed Financial Inc. raised its stake in shares of DexCom by 91.6% in the second quarter. Waddell & Reed Financial Inc. now owns 2,175,574 shares of the medical device company’s stock worth $172,589,000 after buying an additional 1,040,279 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in shares of DexCom by 5.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 2,059,873 shares of the medical device company’s stock worth $163,410,000 after buying an additional 103,319 shares during the last quarter.

Shares of DexCom Inc. (NASDAQ:DXCM) traded down 2.90% during midday trading on Monday, hitting $70.71. 1,009,218 shares of the stock were exchanged. The firm has a 50-day moving average price of $73.82 and a 200-day moving average price of $80.23. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $96.38. The company’s market cap is $5.98 billion.

DXCM has been the topic of a number of research analyst reports. Zacks Investment Research lowered DexCom from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 4th. Canaccord Genuity set a $70.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Monday, November 14th. BMO Capital Markets started coverage on shares of DexCom in a research note on Friday, September 16th. They issued an “outperform” rating and a $112.00 price target for the company. BTIG Research upgraded shares of DexCom from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Monday, October 31st. Finally, Desjardins upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Friday, September 16th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and a consensus target price of $92.07.

In other news, CFO Jess Roper sold 2,471 shares of the firm’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $80.75, for a total value of $199,533.25. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Steven Robert Pacelli sold 10,300 shares of the firm’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $81.95, for a total transaction of $844,085.00. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by insiders.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Related posts

Leave a Comment